Detalles de la búsqueda
1.
Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
J Enzyme Inhib Med Chem
; 38(1): 282-293, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36408835
2.
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Acta Pharmacol Sin
; 42(6): 998-1004, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32918045
3.
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
Acta Pharmacol Sin
; 42(9): 1498-1506, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33288861
4.
Synthesis of triazolotriazine derivatives as c-Met inhibitors.
Mol Divers
; 25(2): 839-846, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32157572
5.
Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core.
Bioorg Med Chem Lett
; 29(6): 836-838, 2019 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30685094
6.
Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Bioorg Med Chem Lett
; 27(11): 2544-2548, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28404375
7.
Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold.
Bioorg Med Chem Lett
; 26(18): 4483-4486, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27524312
8.
Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.
Bioorg Med Chem Lett
; 26(22): 5399-5402, 2016 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27769623
9.
Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Acta Pharmacol Sin
; 37(5): 698-707, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27041462
10.
Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
Bioorg Med Chem Lett
; 30(4): 126931, 2020 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31902709
11.
Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
Bioorg Med Chem
; 23(3): 564-78, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25537530
12.
SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
J Pharmacol Exp Ther
; 350(1): 36-45, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24741075
13.
Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
Molecules
; 19(2): 2655-73, 2014 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24566328
14.
Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
Eur J Med Chem
; 265: 116045, 2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38128234
15.
Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer Treatment.
J Med Chem
; 67(2): 1168-1183, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38227770
16.
Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
Bioorg Med Chem Lett
; 23(8): 2408-13, 2013 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23474386
17.
Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
Org Biomol Chem
; 11(9): 1545-62, 2013 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-23188156
18.
Impact of social integration on metabolic functions: evidence from a nationally representative longitudinal study of US older adults.
BMC Public Health
; 13: 1210, 2013 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24359332
19.
Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.
J Med Chem
; 66(1): 220-234, 2023 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36524812
20.
Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.
J Med Chem
; 66(5): 3226-3249, 2023 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802596